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Abstract: High frequency ( 1 Hz) repetitive transcranial magnetic stimulation (rTMS) 
applied to the left prefrontal cortex and low frequency ( 1 Hz) rTMS applied to the right 
prefrontal cortex have shown antidepressant effects. However, the clinical signiﬁ  cance of 
these effects has often been modest. It was hypothesized that a combination of these two 
techniques might act synergistically and result in more clinically relevant antidepressant 
effects. Sixty-two subjects with treatment-resistant major depression (an average of 8 failed 
medication trials) were randomized to receive combination right low frequency (1 Hz)/left 
high frequency (10 Hz) rTMS over the dorsolateral prefrontal cortex at 110% of the motor 
threshold vs sham rTMS. Subjects were treated for 2 weeks (10 weekday sessions) and received 
1600 stimulations during each treatment session. Subjects receiving combination treatment 
were further randomized to receive different orders of treatment: right low frequency ﬁ  rst 
(Slow Right) vs left high frequency ﬁ  rst (Fast Left). There were no statistical differences in 
the active vs sham treatment arms in the primary outcome variable, the Hamilton Depression 
Rating Scale (HDRS). However compared with subjects in the Sham and Slow Right arms, 
there was a trend for subjects in the Fast Left arm to show improvement in the HDRS, the 
Beck Depression Inventory, and the Brief Psychotic Rating Scale with increased number of 
treatments. The Fast Left arm also showed signiﬁ  cant improvement in both blinded clinician 
and self-ratings of global improvement. These differences were hypothesized to be due to 
the decreased number of failed medication trials for subjects in Fast Left arm. Neuropsycho-
logical performance was not signiﬁ  cantly different between the sham and active rTMS arms. 
Future studies should increase the number of treatment sessions and focus on subjects with 
moderate treatment resistance.
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Introduction
Repetitive transcranial magnetic stimulation (rTMS) provides a minimally invasive 
technique for electrically stimulating and modifying function in the cerebral cortex. 
Research has focused on using rTMS as a treatment for major depression. Given its 
favorable side-effect proﬁ  le, rTMS offers a potentially valuable treatment option for 
subjects who do not tolerate or respond to antidepressant medications and/or elec-
troconvulsive therapy. However, while meta-analyses of rTMS studies in depression 
have shown that rTMS does indeed have statistically signiﬁ  cant antidepressant effects, 
the clinical signiﬁ  cance of these effects has not been satisfactorily demonstrated 
(Holtzheimer et al 2001; Burt et al 2002; Kozel and George 2002; Martin et al 2003). 
For rTMS to become a clinically meaningful treatment for depression, the technique 
must be optimized.
The majority of studies demonstrating antidepressant efﬁ  cacy for rTMS have used 
high frequency ( 1 Hz or “fast”) rTMS over the left dorsolateral prefrontal cortex 
(DLPFC). Mechanistic support for these parameters is provided by (1) evidence 
that the left DLPFC is often hypofunctional in depression (Martinot et al 1990; Neuropsychiatric Disease and Treatment 2006:2(1) 86
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Kennedy et al 1997; Videbech 2000), and (2) evidence that 
fast rTMS can induce lasting increases in cortical excit-
ability (Pascual-Leone et al 1994). A few studies have also 
shown antidepressant efﬁ  cacy for low frequency (  1 Hz or 
“slow”) rTMS applied to the right DLPFC (Klein et al 1999; 
Menkes et al 1999; Fitzgerald et al 2003). Slow rTMS has 
been shown to decrease cortical excitability (Chen et al 1997; 
Wassermann et al 1998), and data suggest some depressed 
subjects may have a hyperfunctional right prefrontal cortex 
(Schaffer et al 1983; Garcia-Toro et al 2001).
Taken together, these data suggest that fast and slow 
rTMS applied to the left and right DLPFCs, respectively, 
may act via reciprocal and potentially complementary mecha-
nisms. It is possible that a combination of these approaches 
could act synergistically to treat depression. While two prior 
sham-controlled studies have used a combination of rTMS 
approaches, both suffered from important limitations. Loo 
et al compared fast rTMS applied to bilateral DLPFCs to 
sham stimulation and found no beneﬁ  t for active rTMS 
(Loo et al 2003). However, fast right-sided rTMS may have 
antimanic rather than antidepressant effects (Michael and 
Erfurth 2004), and the use of this approach may have limited 
the efﬁ  cacy of fast left-sided rTMS. Hausmann et al (2004) 
found no beneﬁ  t for fast left-sided rTMS or combined fast 
left-sided and slow right-sided rTMS in a sham-controlled 
study (Hausmann et al 2004). However, all subjects were 
started on antidepressant medications at the beginning of 
the study, and all 3 arms showed a signiﬁ  cant antidepressant 
response over time. Given the use of an active comparator 
(antidepressant medications in the sham arm), this study 
likely lacked the power to demonstrate a statistical difference 
between the arms.
In this sham-controlled study, the antidepressant effects 
of combined left high frequency and right low frequency 
rTMS were investigated in a treatment-resistant depressed 
population. It was hypothesized that combination rTMS 
would be superior to sham stimulation in treating depres-
sion, and that these antidepressant effects would be clinically 
signiﬁ  cant. In order to determine if the order of the stimulus 
(ie, slow left ﬁ  rst vs slow right ﬁ  rst) made a difference in 
treatment response, the subjects were randomly assigned to 
receive either fast left or slow right ﬁ  rst during treatment 
administration.
Methods
Subjects
This study was reviewed and approved by the Emory 
University Human Investigations Committee. The 62 subjects 
were between 18 and 70 years old recruited from the 
community who met the severity of symptoms speciﬁ  ed by 
the American Psychiatric Association criteria for an acute 
course of electroconvulsive therapy (ECT) (ie, severe major 
depression and intolerant and/or resistant to antidepressant 
medication; Weiner 2001) and had treatment resistance to 
at least 3 antidepressant medications during the present 
depressive episode. Treatment resistance was deﬁ  ned as no 
signiﬁ  cant improvement in depressive symptoms following 
a 6-week trial of an antidepressant dosage equivalent to 
ﬂ  uoxetine 20 mg. The number of previous medication trials 
was determined by self-report and psychiatric record review 
and included the number of failed medication trials in the 
current depressive episode.
After obtaining informed consent, subjects had a 
complete neurological and physical examination with a thor-
ough review of systems. Subjects with minor neurological 
abnormalities (eg, essential tremor, chronic headaches, gait 
ataxia, prior head injury) underwent neuroimaging unless 
they had prior neuroimaging at the onset of the neurologi-
cal dysfunction that showed no gross abnormality. Subjects 
were also screened with a complete blood count, thyroid 
function tests, and electrolytes within 3 months of the treat-
ments. Women of childbearing age were screened with a 
urine pregnancy test.
Subjects were evaluated using a Structured Clinical 
Interview for DSM-IV (SCID) (First et al 1996), Beck 
Depression Inventory (BDI) (Beck et al 1961), Brief Psychi-
atric Rating Scale (BPRS), and the 21-item Hamilton Depres-
sion Rating Scale (HDRS) (Hamilton 1967). Entry criteria 
for the study included meeting SCID criteria for Unipolar 
Depression (UP) or Bipolar Disorder (BP), depressed phase, 
and a score on the 17-item HDRS   20 both at baseline and 
within 24 hours of the ﬁ  rst treatment. Subjects could not have 
active suicidal ideation (deﬁ  ned as a score   2 on question 
nr 9 of the BDI). Subjects were also assessed for handedness 
and educational level by self-report.
Exclusion criteria included evidence of dementia on 
neuropsychological testing (see description of tests below), 
or meeting SCID criteria for Organic Brain Syndrome, 
Organic Mood Disorder, Substance Dependence within 
the last 6 months, a diagnosis of a signiﬁ  cant central neu-
rological disorders including brain mass, epileptic seizures, 
stroke, transient ischemic attack within 2 years, cerebral 
aneurysm, dementia, Parkinson’s disease, Huntington’s 
chorea, multiple sclerosis, or other major CNS dysfunc-
tion. Additional exclusion criteria included pregnancy, the 
presence of cardiac pacemakers, cochlear implants, or other Neuropsychiatric Disease and Treatment 2006:2(1) 87
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intracranial implants with the exception of dental ﬁ  llings, 
and the presence of psychiatric symptoms of signiﬁ  cant 
severity (eg, refusal of food and medication or the presence 
of psychosis) that would prevent a 2-week trial of rTMS 
being tolerated or would require psychiatric hospitalization. 
Subjects that required continued treatment with antide-
pressant medications were excluded. Subjects with acute, 
unstable medical conditions that required stabilization (eg, 
uncontrolled hypertension) prior to treatment were also 
excluded. Subjects were also excluded if they had a previ-
ous course of TMS.
Neuropsychological measures
The Brief Visuospatial Memory Test-Revised (BVMT-R; 
Benedict 1997) was used to evaluate visuospatial memory 
functioning. This measure presents 6 geometric shapes ori-
ented in a 2 by 3 array across 3 study-test trials. The array 
is examined for 10 seconds and is subsequently removed 
from the examinee’s view. The examinee is requested to 
draw the ﬁ  gures as accurately as possible and in the cor-
rect location. One point is awarded for correctly placing 
a ﬁ  gure in its proper location, and one point is awarded 
for drawing the ﬁ  gure accurately. A total of 12 points are 
possible on any trial. Age-corrected T-scores (mean of 
50, SD of 10) are computed on the basis of raw scores for 
each trial, for the sum of trials 1 through 3 (immediate 
memory), and for a 30-minute delayed recall of the ﬁ  gures. 
There are 6 alternative forms that may be administered to 
reduce practice effects. Forms 1 and 2 were administered 
in counterbalanced fashion, such that half of the subjects 
received Form 1 at Day 0 followed by Form 2 at Day 10 
and half of the subjects received Form 2 ﬁ  rst, followed 
by Form 1.
The Repeatable Battery for the Assessment of Neu-
ropsychological Status (RBANS; [Randolph 1988]) was 
used to evaluate level of performance across 5 cognitive 
domains (Immediate Memory, Visuospatial Functioning, 
Language, Attention, Delayed Memory). It also provides 
a summary total score. The measure takes approximately 
25–35 minutes to administer, and it yields age-corrected 
standard scores (mean = 100, SD = 10) for each cognitive 
domain and for the total score. Two parallel forms (Forms A 
and B) are available that can be used to reduce the effects 
of repeated practice. As with the BVMT-R, Forms 1 and 2 
were administered in counterbalanced fashion, such that 
half of the subjects received Form A at Day 0 followed by 
Form B at Day 10 and half of the subjects received Form B 
ﬁ  rst, followed by Form A.
Finally, a Verbal Letter Fluency task (Benton and des 
Hamsher 1983) was used to evaluate cognitive ﬂ  exibility. 
This task required the examinee to generate as many words 
as possible beginning with a speciﬁ  c letter in 60 seconds; 
2 different letters are administered for each of 2 forms. As 
with the other neuropsychological measures, the 2 forms 
(CFL and PRW) were administered in counterbalanced 
fashion. The dependent variable for this task was the 
total number of words generated across 3 60-second trials 
(1 60-second trial for each of 3 letters).
Procedures
The device was a Neuronetics High Speed Magnetic 
Stimulator (Neuronetics Inc, Malvern PA, USA) with a 
maximum output of 2 Tesla. The magnetic conﬁ  guration is a 
ﬁ  gure-8 with an iron core that has an induced ﬁ  eld conﬁ  gura-
tion with increased efﬁ  ciency (Epstein and Davey 2002).
At each treatment, the subject’s motor threshold was 
determined using the method of limits and all rTMS dos-
ing was administered relative to this value. Motor-evoked 
potentials from muscles in the hand were elicited with 
single-pulse magnetic stimulation over the left hemisphere. 
After determination of the point of maximal stimulation 
for the contralateral thumb, the method of limits was 
used to ﬁ  nd the motor threshold for that individual (the 
lowest stimulation intensity capable of inducing 5 motor 
responses in a series of 10 single magnetic stimuli with 
the coil centered over the optimal scalp position). Once 
the optimal area to evoke the MT was determined, the 
coil was moved 5 cm anterior to treat over the dorsolateral 
prefrontal cortex.
Subjects were randomized to either sham TMS or a 
combination of Fast Left (10 Hz) rTMS over the DLPFC 
followed by Slow Right (1 Hz) DLPFC rTMS or Slow Right 
followed by Fast Left rTMS in a 1:2:2 ratio, respectively. 
Sham TMS was administered by tilting the stimulator at a 
90-degree angle to the skull so that the electromagnetic pulse 
is directed away from the cortex and is essentially ineffec-
tive. Combination fast and slow rTMS was administered at 
110% motor threshold (MT), with 20 5-second stimulations 
over 10 minutes of 10 Hz over the left DLPFC (total of 
1000 stimulations) and 10 minutes of 1 Hz stimulation over 
the right DLPFC respectively (total of 600 stimulations). 
Stimulations were administered for 10 days separated by 
the weekend.
The subject and/or a research assistant blind to the 
randomization completed all clinical measures at baseline 
(within 24 hours before the ﬁ  rst treatment), and after the Neuropsychiatric Disease and Treatment 2006:2(1) 88
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5th and 10th treatment. The measures included the HDRS, 
BDI, and 7-point Clinical Global Improvement Scale (CGI). 
The RBANS, BVMT-R, and Verbal Fluency measures were 
used to monitor for cognitive effects of rTMS. The neu-
ropsychological battery was administered at baseline and 
after the 10th treatment. The HDRS score was the primary 
measure of efﬁ  cacy and remission of symptoms was deﬁ  ned 
as HDRS   7 (Ballinger 1999). Treatment response was 
deﬁ  ned as a 50% or more decline in the HDRS compared 
with baseline (Frank et al 1991). Subjects who remitted or 
who showed a partial treatment response after 10 treatments 
were assessed 2 weeks, 1 month, 2 months, and 3 months 
after the last treatment to determine if they relapsed (ie, met 
SCID criteria for a major depression).
Statistical analyses
The primary analysis of the data was performed according 
to subjects’ original treatment assignment (ie, an intention-
to-treat analysis) and all subjects were included in the 
analyses for as long as they contributed data. Baseline 
characteristics between treatment arms were compared 
with the Kruskal-Wallis test for continuous variables and 
with the χ2 or Fisher’s exact test for proportions. Change in 
CGI over time for each treatment arm was compared with 
the sign test.
The data were analyzed both as a comparison of the 
combined active vs sham treatment arms and a comparison 
on the 3 arms (Fast Left First, Slow Right Rirst, and Sham). 
The latter comparison was done to determine the effect of 
the order of treatment administration on treatment response. 
Repeated-measures analyses for HDRS, CGI, BDI, and 
BPRS and percent change from baseline were analyzed with a 
means model with SAS Proc Mixed (version 8; SAS Institute 
Inc., Cary, NC, USA), providing separate estimates of the 
means by time on study and treatment arm. An unstructured 
variance-covariance form among the repeated measurements 
was assumed for each outcome and estimates of the standard 
errors of parameters were used to perform statistical tests 
and construct 95% conﬁ  dence intervals. T-tests were used to 
compare the pair-wise differences between the model-based 
treatment means (least-squares means) at each time point. 
The model-based means are unbiased with unbalanced and 
missing data, if the missing data are noninformative (miss-
ing at random). A dropout process is assumed to be missing 
at random if, conditional on the observed data, the dropout 
is independent of the unobserved measurements. Statistical 
tests were 2-sided. A Bonferroni adjustment (p   0.0167) 
was used for the 3 pair-wise comparisons performed at each 
time point.
For each neuropsychological measure, a 3 (arm–placebo, 
Fast Left First, Slow Right First) by 2 (Time–Day 0 vs Day 
10) mixed design analysis of variance (ANOVA) was per-
formed using SPSS (SPSS Inc, Chicago, IL, USA) Version 
12.0.2. The General Linear Model procedure was used to 
evaluate main effects of Arm and Time of Treatment, as well 
as the interaction between Arm and Time.
Results
Subjects were randomized into 3 arms in a 1:2:2 ratio: Sham 
stimulation (n = 12), combination active treatment with 
Table 1 Demographic and clinical characteristics by randomization arm: the demographic and clinical characteristics of the subjects 
divided by whether they received 2 weeks of sham transcranial magnetic stimulation (TMS) or combination fast left and slow right 
TMS starting with either Fast Left treatments or Slow Right treatments. Signiﬁ  cant differences were noted in the number of medica-
tion trials subjects received prior to TMS
Variable Sham (n = 12) Fast Left (n = 25) Slow Right (n = 25) p
Median (P25, P75)a
Age (years) 54.0 (47.0, 64.0) 49.0 (41.0, 55.0) 49.0 (39.0, 54.0) 0.24
Education (years) 14.0 (12.0, 16.0) 16.0 (14.0, 17.0) 16.0 (14.0, 18.0) 0.21
# previous medication trials 6.5 (5.0, 11.0) 7.0 (5.0, 9.0) 10.0 (8.0, 13.0) 0.003
% (n)
% male 58.3 (7) 28.0 (7) 64.0 (16) 0.03
% bipolar 25.0 (3) 20.0 (5) 0.0 (0) 0.03
% right hand dominant 66.7 (8) 96.0 (24) 76.0 (19) 0.05
% previous ECT 50.0 (6) 28.0 (7) 54.2 (13) 0.15
% attempted suicide 16.7 (2) 12.0 (3) 12.5 (3) 1.00
a Entries are the median, the 25th, and 75th percentiles (P25, P75) for continuous variables; % (frequency) for categorical variables.Neuropsychiatric Disease and Treatment 2006:2(1) 89
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fast left then slow right (Fast Left; n = 25) or combination 
treatment with slow right followed by fast left (Slow Right; 
n = 25). The summary of the demographic and clinical char-
acteristics of the study population is outlined in Table 1.
The subjects were treatment resistant. The median num-
ber of failed medication trials prior to study entry was 8, and 
43% of subjects had failed ECT. The Slow Right arm had 
the highest number of failed trials of medication (p = 0.006), 
fewer male (p = 0.03) and bipolar subjects (p = 0.03). The 
Fast Left arm had all but 1 subject who was right hand 
dominant (p = 0.05).
Only 3 subjects remitted by the a priori diagnosis of a 
ﬁ  nal HDRS   7. The 3 subjects were all in the Fast Left arm 
(12% remitted in the Fast Left arm; 4.8% of all subjects). 
Including the remitted subjects, 11 of the 62 subjects (18% 
of all subjects) met criteria for treatment response (ie, 50% 
decline in the HDRS): 7/25 (28%) Fast Left, 3/25 (12%) Slow 
Right, 1 Placebo (8%). This was a nonsigniﬁ  cant difference, 
which showed a trend for improvement with the subjects who 
received Fast Left treatment ﬁ  rst.
Although subjects were allowed to remain on psychotro-
pic medications except for antidepressants, only 6 subjects 
were on medications and none of these subjects responded to 
treatment. The daily doses of medication for these 6 subjects 
were: (1) lorazepam 1 mg and zolpidem 10 mg; (2) lorazepam 
1 mg; (3) risperidone 3 mg; (4) zaleplon 5 mg; (5) lorazepam 
0.5 mg; (6) lorazepam 0.5 mg.
Figures 1a and 1b show the mean change in the HDRS and 
the BDI over 2 weeks comparing the sham arm with active 
stimulation (ie, Fast Left and Slow Right combined). There 
was no signiﬁ  cant change in either the total observer-rated 
HDRS or self-rated BDI scores, although the BDI for the 
active stimulation arm did show a clear trend toward improv-
ing (lower score) with an increased number of treatments and 
the BDI in the sham arm remained ﬂ  at. There was also no 
signiﬁ  cant change in the BPRS (not shown).
Mean HDRS in the 3 study arms were similar at baseline 
(p = 0.23) and the mean HDRS scores declined in all 3 arms 
from baseline to day 10. After the 10th treatment, mean 
HDRS was 19.8, 16.2, and 22.3 for Sham, Fast Left, and 
Slow Right arms respectively. The mean difference of 6.1 
(22.3–16.3) between Slow Right and Fast Left in HDRS at 
day 10 was statistically signiﬁ  cant (p = 0.007).
Mean BDI in the 3 study arms were similar at baseline 
(p = 0.18). Mean BDI did not change over time for the Sham 
arm but mean BDI did decline over time in the Fast Left and 
Slow Right arms. After the 10th treatment, mean BDI was 
22.8, 15.3, and 22.8 for Sham, Fast Left, and Slow Right 
arms, respectively. The mean differences in BDI between 
Sham and Fast Left at day 10 (mean difference = 7.5, 
p = 0.07) and Slow Right and Fast Left (mean difference = 
7.5, p = 0.02) were not statistically signiﬁ  cant based on the 
Bonferroni adjustment.
The mean percentage decline from baseline in HDRS was 
similar for the 3 arms after the 5th treatment (p = 0.51). After 
the 10th treatment, the percentage decline from baseline in 
HDRS was 29.4%, 37.4%, and 19.4% for Sham, Fast Left, 
and Slow Right arms, respectively (p = 0.014 for Fast Left 
vs Slow Right, Figure 2a).
The BDI in the 3 study arms changed in signiﬁ  cantly 
different ways during treatment (p = 0.003, test for 
interaction between time on study and treatment arm). 
The difference in the pattern of change is best seen by 
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Figure 1a Change in the Hamilton Depression Rating Scale (HDRS) over the 
10 days of active vs Sham treatment showing a change in the absolute scores over 
time without a signiﬁ  cant difference between and Sham and active treatment.
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Figure 1b Change in the Beck Depression Inventory (BDI) over the 10 days 
of active vs Sham treatment showing a change in the absolute scores over time 
without a signiﬁ  cant difference between Sham and active treatment. There is a 
trend over time for the BDI to improve in the active group compared with the lack 
of any change in the Sham group.Neuropsychiatric Disease and Treatment 2006:2(1) 90
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to day 10 was signiﬁ  cantly different between Sham and 
Fast Left (p = 0.007) but not statistically different between 
Sham and Slow Right (p = 0.41) and Fast Left and Slow 
Right (p = 0.02).
Repeated-measures analyses of BDI were performed 
separately for several baseline covariates in order to adjust 
the analyses for covariates. Each baseline covariate was 
included as a factor in the repeated-measures analyses 
along with treatment arm, time on study, and the interac-
tion between treatment arm and time on study. BDI was 
not signiﬁ  cantly different based on the number of failed 
trials of medication (p = 0.10), gender (p = 0.51), bipolar 
diagnosis (p = 0.82), hand dominance (p = 0.74), or failure 
of previous ECT (p = 0.45). These analyses were also per-
formed for HDRS, and baseline covariates did not affect 
the HDRS results.
Mean BPRS in the 3 study arms were similar at baseline 
(p = 0.11) and after the 5th treatment (p = 0.71) and after 
the 10th treatment (p = 0.25). Again, however, the pattern 
of change in Figure 2c shows a decline in the BPRS from 
day 5 to day 10 in the Fast Left arm and a small increase in 
the BPRS for the Slow Right and Sham arms.
In summary, all 3 measures of psychopathology tended 
to level off after the ﬁ  rst 5 treatments in the Sham and Slow 
Right arms, whereas the Fast Left arm appeared to continue 
to show improvement through the 10th or ﬁ  nal treatment. 
This is best illustrated in Figures 2a and 2b which show the 
mean percentage of improvement in the HDRS and BDI, 
respectively. The BDI improved markedly for the Fast Left 
arm from days 5 to 10 and was relatively stable for Sham 
and Slow Right arms. This pattern was similar for the HDRS 
although not quite as marked.
Table 2 summarizes the CGI data. The Fast Left arm 
showed a signiﬁ  cant improvement over time with treatment, 
whereas the other two arms were relatively stable. There was 
a shift towards improvement between days 5 and 10 in both 
the subject (P = 0.006) and clinician (p = 0.003)-rated CGI 
data for the Fast Left arm.
A univariate analysis of both the BDI and HDRS scores 
over time showed that there was no interaction between 
time and treatment, and therefore there was no signiﬁ  cant 
improvement in depression in the Fast Left or Slow Right 
arms compared with Sham at day 5 or day 10. However, the 
CGI data in Table 2 indicate that the Fast Left arm again 
showed a tendency to improve over time with treatment, 
whereas the other 2 arms were relatively stable.
A univariate analysis was conducted using the HDRS as 
the response of interest. The main variables were treatment 
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Figure 2 The percentage change and 95% conﬁ  dence intervals in Hamilton 
Depression Rating Scale (HDRS) (a); Beck Depression Inventory (BDI) (b); 
and Brief Psychotic Rating Scale (BPRS) (c).   All 3 groups showed an improve-
ment over the 2 weeks. The Fast Left group showed continued improvement 
(ie, continued decrease in the HDRS, BDI, and BPRS) in the second week of the 
study, whereas the Slow Right and Sham groups appeared to level off or show no 
improvement.
comparing the percentage change from baseline to day 10 
(Sham arm, mean change = 13.5%; Fast Left arm, mean 
change = 42.2%; Slow Right, mean change = 22.0%, 
Figure 2b). The mean percentage decline from baseline Neuropsychiatric Disease and Treatment 2006:2(1) 91
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(Sham, Fast Left, and Slow Right), and time (Day 1, Day 5, 
and Day 10). Other variables included gender, age, education 
in years, handedness (left–right), diagnosis (bipolar or unipolar 
depression), have had ECT before (Yes/No), working at treat-
ment time (Yes/No), the number of suicide attempts, and the 
number of previous medication trials. Race was not included 
since all but one subject was Caucasian. Only the number of 
previous medication trials approached signiﬁ  cance (F = 3.94, 
df = 58, p = 0.052). A mixed-model univariate analysis con-
ducted after adjusting for demographic variables showed that 
previous medication trials (F = 7.21, df = 56, p = 0.0095) and 
medication trials x time (F = 5.99, df = 103, p = 0.0035) were 
signiﬁ  cant, whereas medication trials × treatment approached 
signiﬁ  cance (F = 3.94, df = 56, p = 0.0250).
Neuropsychological measures
Means and standard deviations for each of the 3 arms across 
both time periods are presented in Table 3. There was no 
signiﬁ  cant (p   0.05) Arm by Time interaction effects or 
Arm main effects for any of the dependent variables studied. 
A signiﬁ  cant Time main effect was observed for RBANS 
Immediate Memory (F(1,48) = 4.49, p   0.04) and for Ver-
bal Letter Fluency (F(1,47) = 7.31, p   0.01), reﬂ  ecting a 
signiﬁ  cant improvement at Day 10 relative to Day 0 across 
all 3 arms. A signiﬁ  cant Time main effect was also observed 
for the RBANS Language Index (F(1,48) = 25.10, p   0.001), 
reﬂ  ecting a signiﬁ  cant decline across all three arms at Day 10 
relative to Day 0. Inspection of performance on subtests 
Table 2 Patients’ and blinded raters’ assessed improvement 
on the 7 point Clinical Global Improvement (CGI) scale which 
ranged from –3 (markedly worse mood) to +3 (markedly 
improved mood). The percentage of +2 (much improved) 
and +3 scores are presented; dropouts were counted as 0 or no 
change
Day 5 Day 10
CGI patient
Sham 8.3% 16.6%
Fast Left 16% 48%
Fast Right 4% 12%
CGI rater
Sham 8.3% 8.3%
Fast Left 16% 52%
Fast Right 8% 8%
Table 3 Means and standard deviations for neuropsychological measures across group and time
Group
Placebo 
(n = 11)
Fast Left First 
(n = 20)
Slow Right First 
(n = 20)
Mean SD Mean SD Mean SD
BVMT Immediate Day 0 31.73 11.31 37.95 11.81 32.30 10.51
BVMT Immediate Day 10 31.45 8.25 39.95 12.33 33.85 10.63
BVMT Delayed Day 0 29.45 10.91 41.00 12.63 33.20 11.87
BVMT Delayed Day 10 34.55 12.75 38.55 12.58 33.90 11.05
RBANS Immediate Memory Day 0 98.73 15.20 103.20 18.54 95.90 14.24
RBANS Immediate Memory Day 10 99.82 13.56 106.55 15.62 102.20 17.17
RBANS Visuospatial Day 0 91.27 18.54 88.70 16.78 79.80 15.72
RBANS Visuospatial Day 10 84.27 15.15 90.50 12.23 81.20 17.46
RBANS Language Day 0 89.00 14.00 96.55 9.23 92.20 14.51
RBANS Language Day 10 81.55 9.76 88.40 11.16 85.85 11.03
RBANS Attention Day 0 88.36 21.74 95.15 18.71 97.58a 14.98
RBANS Attention Day 10 91.64 21.29 100.40 17.04 97.32a 13.10
RBANS Delayed Memory Day 0 92.00 12.20 96.40 14.46 94.37a 10.93
RBANS Delayed Memory Day 10 90.45 13.21 98.10 12.64 92.32a 16.06
RBANS Total Score Day 0 89.18 17.04 94.60 15.21 89.95a 9.15
RBANS Total Score Day 10 85.91 13.82 95.55 14.38 89.95a 11.38
Verbal Letter Fluency Day 0 34.55 14.71 35.00 12.99 36.53a 12.05
Verbal Letter Fluency Day 10 36.09 14.31 40.20 15.60 38.05a 12.78
an = 19 for Slow Right First group.
Abbreviations: BVMT, Brief Visuospatial Memory Test-Revised; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SD, standard deviation.Neuropsychiatric Disease and Treatment 2006:2(1) 92
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making up this Index revealed signiﬁ  cant differences across 
all three arms on a verbal category member generation task 
in which participants were asked to generate as many animal 
names as possible (Form A) or as many fruits and vegetables 
as possible (Form B). Performance was signiﬁ  cantly lower 
across all 3 arms at the Day 10 assessment point.
The subjects who met criteria for response and remis-
sion (n = 11) were assessed at 2 weeks, 1 month, 2 months, 
and 3 months post TMS. Their treating physician started 
subjects on medications although some subjects and their 
doctors chose not to start on medications because of previ-
ous intolerance or lack of response. Two subjects refused 
further follow-up. One of these subjects had a ﬁ  nal HDRS 
of 8 and the other had a ﬁ  nal HDRS of 9. The treatment and 
maintenance data on the remaining 9 subjects are outlined in 
Table 4. Three subjects met criteria for remission: 1 subject 
remained well on ﬂ  uoxetine and olanzapine and 2 other 
subjects relapsed in 2 weeks, 1 bipolar subject on a combina-
tion of lithium and carbamazepine and a second subject with 
unipolar depression relapsed on no medication. Six subjects 
met criteria for treatment response: 1 subject remained 
well through 2 months on no medication and was then lost 
to follow-up; 1 subject remained well through 3 months on 
no medication; and 4 subjects relapsed. Of the subjects who 
relapsed: 1 subject relapsed at 2 weeks on lorazepam and 
tranylcypromine; 2 subjects relapsed at 1 month, 1 on olan-
zapine and valproic acid and 1 on no medication; 1 subject 
relapsed at 3 months on paroxetine.
Discussion
This study evaluated the acute and long-term efﬁ  cacy of 
combined slow right and fast left stimulation of the DLPFC 
in subjects with treatment-resistant depression. The subjects 
in this study met criteria for ECT and almost half had failed 
a trial of ECT prior to rTMS. The average number of failed 
medication trials was approximately 8.5. Both the Sham 
and Combination treatment arms showed improvement with 
time although there was no clear treatment effect for active 
rTMS. The one clinical variable that did appear to have a 
signiﬁ  cant effect on response was an improved response with 
a decreased number of previous failed medication trials. This 
ﬁ  nding is not surprising and may be a measure of treatment 
resistance. In addition this observation is similar to data from 
ECT studies (eg, Sackeim et al 1990), which correlates poor 
response to ECT with previous medication failures. The fact 
that a previous poor response to ECT was not associated with 
poor response to rTMS replicates earlier work that showed 
that subjects may respond differentially to ECT and rTMS 
(Janicak et al 2002). It is also noteworthy that there were no 
differences in neuropsychological functioning across the 
sham and the active arms, suggesting the relative safety of 
both rTMS procedures over the 10-day treatment period.
The data showed a trend for subjects who received Fast 
Left treatments ﬁ  rst to have a better response as indicated by 
nonsigniﬁ  cant improvements in the HDRS and signiﬁ  cant 
improvements in the BDI in the second week, together with 
an improved rating on both the clinician and subject rated 
global improvement scale. The ﬁ  nding was most likely due 
to the fact that the subjects in this arm had fewer previous 
medication trials and were less ill. Others have cited evidence 
that the level of pharmacological treatment resistance may 
have a negative correlation with response to TMS (Gershon 
et al 2003).
However the possibility that administering Slow Right 
ﬁ  rst somehow impeded the efﬁ  cacy of Fast Left or, alterna-
tively, Fast Left First improved the response to Slow Right 
Table 4 Time to relapse after response to an acute course of transcranial magnetic stimulation
Randomization
Final 
HDRS Maintenance medication Time to relapsea
Fast Left 2 zaleplon 10 mg, lithium 600 mg, carbamezepine 800 mg, lorazepam 1 mg 2 weeks
Fast Left 4 No medication 2 weeks
Fast Left 7 ﬂ  uoxetine 20 mg, quetiapine 400 mg No relapse
Fast Left 8 No medication No relapse
Fast Left 10 lorazepam 1 mg bid, tranylcypromine 10 mg bid 2 weeks
Sham 10 No medication 1 month
Slow Right 10 paroxetine 10 mg 3 months
Slow Right 15 Olanzapine 10 mg qhs, valproic acid 250 mg bid 1 month
Slow Right 17 No medication 2 months (not seen at 3 months)
aSubjects were started on medication by the treating physician and assessed at 2 weeks, 1, 2, and 3 months to determine if they met criteria for relapse.
Abbreviations: HDRS, Hamilton Depression Rating Score.Neuropsychiatric Disease and Treatment 2006:2(1) 93
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cannot be ruled out in this study. Another possibility is that 
the HDRS, which is weighted toward somatic symptoms 
of depression (eg, sleep and appetite disturbances), was 
not sensitive enough to detect the improvement noted on 
the CGI.
There are several possible reasons why the active 
treatments did not differentiate from Sham. First, the total 
number of stimulations for a given treatment setting was 
relatively low (1600) and the total number of sessions was 
only 10. Both the number of pulses and the quantity of pulses 
have been shown to be directly correlated with treatment 
response (Gershon et al 2003). And although our study is 
one of the larger randomized controlled trials using rTMS, 
the sample size may have been too small to detect a differ-
ence in the groups (ie, Type II error).
The ﬁ  nding that the subjects in the Fast Left arm were 
improving in week 2 leaves open the question of whether 
they would have continued to improve with additional treat-
ment sessions. Overall, the subjects in this study were very 
treatment resistant, and half had failed ECT, which makes 
the ﬁ  nding of improvement on the BDI and CGI encourag-
ing. In retrospect, the use of rTMS as an augmenting agent 
to the antidepressant the subject was taking at the time of 
initial evaluation may have been more appropriate. Most 
subjects were having at least a partial response to these 
medications, although they still met severity criteria for 
entry into the study.
Our arm is a part of 2 multicenter trials (1 industry spon-
sored and the other sponsored by the National Institute of 
Mental Health). Both trials screen subjects for only moderate 
treatment resistance (1–3 medication failures), increase the 
number of stimulations per session, and use a more ﬂ  exible 
treatment design which allows the treating clinician to treat 
subjects up to 6 weeks. Data from the present study support 
the use of this modiﬁ  ed rTMS treatment protocol in major 
depression.
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